When good nutrients go bad: Can we predict nutrientdrug interactions?

British Journal of Nutrition

Volumn 102, Issue 3, 2009, Pages 334-336

  Meckling, Kelly Anne ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GLUTAMINE; HERBACEOUS AGENT; IRINOTECAN; OMEGA 3 FATTY ACID; TRACE ELEMENT;

ALTERNATIVE MEDICINE; ANOREXIA; CACHEXIA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; COLON CARCINOMA; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FOOD; FOOD DRUG INTERACTION; GENE INTERACTION; GENETIC POLYMORPHISM; HUMAN; MACRONUTRIENT; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; NONHUMAN; NOTE; NUTRIENT; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; PRIMARY MEDICAL CARE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; IMMUNOLOGY; NEOPLASM;

CARDIOVASCULAR DISEASES; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FOOD-DRUG INTERACTIONS; GLUTAMINE; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 70149115023     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114508199494     Document Type: Note

References (39)

1. Boon H, Stewart M, Kennard MA, et al. (2000) Use of complementary/ alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18, 2515-2521.
2. Boon H, Westlake K, Stewart M, et al. (2003) Use of complementary/ alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology 62, 849-853.
3. Salminen E, Bishop M, Poussa T, et al. (2004) Dietary attitudes and changes as well as use of supplements and complementary therapies by Australian and Finnish women following the diagnosis of breast cancer. Eur J Clin Nutr 58, 137-144.
4. Kelly KM, Jacobson JS, Kennedy DD, et al. (2000) Use of unconventional therapies by children with cancer at an urban medical center. J Pediatr Hematol Oncol 22, 412-416.
5. Meckling K (2007) Nutrient-Drug Interactions. Boca Raton, FL: CRC Press, Taylor & Francis.
6. Sacco SM, Power KA, Chen J, et al. (2007) Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice. Exp Biol Med (Maywood) 232, 754-761.
7. Zou W, Yue P, Lin N, et al. (2006) Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12, 273-280.
8. Xue H, Le Roy S, Sawyer MB, et al. (2009) Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl- 10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour. Br J Nutr 102, 434-442.
9. Kaibara A, Yoshida S, Yamasaki K, et al. (1994) Effect of glutamine and chemotherapy on protein metabolism in tumor-bearing rats. J Surg Res 57, 143-149.
10. Yoshida S, Kaibara A, Ishibashi N, et al. (2001) Glutamine supplementation in cancer patients. Nutrition 17, 766-768.
11. Yoshida S, Kaibara A, Yamasaki K, et al. (1995) Effect of glutamine supplementation on protein metabolism and glutathione in tumor-bearing rats. JPEN J Parenter Enteral Nutr 19, 492-497.
12. Barber MD, Ross JA & Fearon KC (1998) The anti-cachectic effect of fatty acids. Proc Nutr Soc 57, 571-576.
13. Hardman WE (2004) (n-3) Fatty acids and cancer therapy. J Nutr 134, 3427S-3430S.
14. Moses AW, Slater C, Preston T, et al. (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90, 996-1002.
15. Cave WT Jr (1991) Dietary n-3 (omega-3) polyunsaturated fatty acid effects on animal tumorigenesis. FASEB J 5, 2160-2166.
16. Hardman WE, Sun L, Short N, et al. (2005) Dietary omega-3 fatty acids and ionizing irradiation on human breast cancer xenograft growth and angiogenesis. Cancer Cell Int 5, 12.
17. Atkinson TG, Barker HJ & Meckling-Gill KA (1997) Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in postweanling Fischer 344 rats. Lipids 32, 293-302.
18. Jordan A & Stein J (2003) Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. Eur J Nutr 42, 324-331.
19. Menendez JA, Lupu R & Colomer R (2005) Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22:6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur J Cancer Prev 14, 263-270.
20. Nakamura K, Kariyazono H, Komokata T, et al. (2005) Influence of preoperative administration of omega-3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. Nutrition 21, 639-649.
21. Rose DP, Connolly JM & Coleman M (1996) Effect of omega-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. Clin Cancer Res 2, 1751-1756.
22. Shao Y, Pardini L & Pardini RS (1994) Enhancement of the antineoplastic effect of mitomycin C by dietary fat. Cancer Res 54, 6452-6457.
23. Kato T, Hancock RL, Mohammadpour H, et al. (2002) Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett 187, 169-177.
24. Mohammadpour H, Hall MR, Pardini RS, et al. (2000) Tumor development and cytokine production by human colon tissues and carcinoma cell lines. Int J Surg Investig 2, 65-72.
25. Shao Y, Pardini L & Pardini RS (1997) Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Nutr Cancer 28, 63-73.
26. Bougnoux P, Maillard V, Ferrari P, et al. (2002) n-3 fatty acids and breast cancer. IARC Sci Publ 156, 337-341.
27. Atkinson TG, Murray L, Berry DM, et al. (1997) DHA feeding provides host protection and prevents fibrosarcoma-induced hyperlipidemia while maintaining the tumor response to araC in Fischer 344 rats. Nutr Cancer 28, 225-235.
28. De Salis H & Meckling-Gill KA (1995) EPA and DHA alter nucleoside drug and adriamycin toxicity in L1210 leukemia cells but not in normal bone marrow derived S1 macrophages. Cell Pharmacol 2, 69-74.
29. Cha MC, Meckling KA&Stewart C (2002) Dietary docosahexaenoic acid levels influence the outcome of arabinosylcytosine chemotherapy in l1210 leukemic mice. Nutr Cancer 44, 176-181.
30. Cha MC, Lin A & Meckling KA (2005) Low dose docosahexaenoic acid protects normal colonic epithelial cells from araC toxicity. BMC Pharmacol 5, 7.
31. Wynter MP, Russell ST & Tisdale MJ (2004) Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs. In Vivo 18, 543-547.
32. Savarese DM, Savy G, Vahdat L, et al. (2003) Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29, 501-513.
33. Coghlin Dickson TM, Wong RM, Offrin RS, et al. (2000) Effect of oral glutamine supplementation during bone marrow transplantation. JPEN J Parenter Enteral Nutr 24, 61-66.
34. Piccirillo N, De Matteis S, Laurenti L, et al. (2003) Glutamineenriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica 88, 192-200.
35. Xue H, Sawyer MB, Field CJ, et al. (2007) Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin Cancer Res 13, 7146-7154.
36. Xue H, Sawyer MB, Field CJ, et al. (2008) Bolus oral glutamine protects rats against CPT-11-induced diarrhea and differentially activates cytoprotective mechanisms in host intestine but not tumor. J Nutr 138, 740-746.
37. Di CV, Gianotti L, Balzano G, et al. (1999) Complications of pancreatic surgery and the role of perioperative nutrition. Dig Surg 16, 320-326.
38. Heller AR, Rossel T, Gottschlich B, et al. (2004) Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Int J Cancer 111, 611-616.
39. Gianotti L, Braga M, Fortis C, et al. (1999) A prospective, randomized clinical trial on perioperative feeding with an arginine-, omega-3 fatty acid-, and RNA-enriched enteral diet: effect on host response and nutritional status. JPEN J Parenter Enteral Nutr 23, 314-320.